Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Your immune system never forgets — and that's a problem for cancer patients with joint pain. Researchers from Yale and MD Anderson found that recurring arthritis triggered by immune checkpoint inhibitors is driven by immune cells that "remember" previous flares and return in greater numbers. The discovery could help predict and prevent painful joint flares without compromising cancer-fighting treatment.
For some cancer patients, immune checkpoint inhibitors come with an unwanted side effect: inflammatory arthritis that doesn't just go away — it keeps coming back, often more severely. Now, researchers from Yale University and UT MD Anderson Cancer Center think they know why.
The team analyzed joint fluid from patients during both their first and second arthritis flares. They found that two specific immune cell populations — inflammatory CD8 T cells and a specialized group of CD4 T cells marked by PD-1 and CXCL13 — were present during both episodes and grew more numerous and active over time. The pattern points to immune memory: rather than launching a fresh attack, the immune system appears to be reactivating a response it already "learned."
In a surprising twist, regulatory T cells — normally the immune system's brakes — were also found to be producing inflammatory molecules during recurring flares, potentially making it harder for the body to shut the response down.
Key Takeaways:
Why it matters: Arthritis flares can be severe enough to interrupt life-saving cancer therapy. Understanding the immune memory mechanism behind recurrence opens the door to more targeted interventions — ones that protect joints without blunting the immune system's ability to fight tumors.